中华微生物学和免疫学杂志
中華微生物學和免疫學雜誌
중화미생물학화면역학잡지
CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY
2014年
8期
630-634
,共5页
李晓阳%郭学青%李宁一%陈立%吴超
李曉暘%郭學青%李寧一%陳立%吳超
리효양%곽학청%리저일%진립%오초
幽门螺杆菌%CD4+T细胞%表位
幽門螺桿菌%CD4+T細胞%錶位
유문라간균%CD4+T세포%표위
Helicobacter pylori%CD4+T cell%Epitope
目的:建立幽门螺杆菌( Helicobacter pylori,H.pylori)抗原特异性CD4+T细胞体外扩增方法,并在Th表位筛选中初步应用。方法从H.pylori感染阳性患者中分离外周血单个核细胞(PBMC),以重组黏附素抗原(HpaA)进行体外刺激,分别摸索不同血清培养基、抗原刺激浓度、培养时间等体外扩增条件,并通过细胞内因子染色和流式细胞技术检测HpaA特异性CD4+T细胞产生IFN-γ应答水平,从而建立H.pylori感染者抗原特异性CD4+T淋巴细胞的体外扩增方法。同时,结合合成重叠肽技术,对抗原HpaA中可能的Th表位进行初步筛查。结果在含人AB血清的1640培养基中培养的抗原特异性CD4+T细胞的扩增效率优于含胎牛血清的1640培养基; HpaA抗原初刺激浓度为0.2μmol/L时,抗原特异性CD4+T细胞的比例最高;在抗原刺激浓度0.2μmol/L条件下,细胞培养9 d时出现特异性CD4+T细胞应答,且在第15天时达到高峰值;以不同肽段对特异性CD4+T细胞的IFN-γ应答水平检测分析中显示:针对本研究H.pylori感染个体,HpaA抗原中可能存在一个优势应答的Th细胞表位(HpaA220-237)。结论在人AB血清的1640培养基,0.2μmol/L为抗原刺激浓度,连续15 d扩增等培养条件下,在体外成功扩增出H.pylori抗原特异性CD4+T淋巴细胞,可用于H.pylori抗原中Th表位的筛选和鉴定,为表位疫苗研究奠定实验基础。
目的:建立幽門螺桿菌( Helicobacter pylori,H.pylori)抗原特異性CD4+T細胞體外擴增方法,併在Th錶位篩選中初步應用。方法從H.pylori感染暘性患者中分離外週血單箇覈細胞(PBMC),以重組黏附素抗原(HpaA)進行體外刺激,分彆摸索不同血清培養基、抗原刺激濃度、培養時間等體外擴增條件,併通過細胞內因子染色和流式細胞技術檢測HpaA特異性CD4+T細胞產生IFN-γ應答水平,從而建立H.pylori感染者抗原特異性CD4+T淋巴細胞的體外擴增方法。同時,結閤閤成重疊肽技術,對抗原HpaA中可能的Th錶位進行初步篩查。結果在含人AB血清的1640培養基中培養的抗原特異性CD4+T細胞的擴增效率優于含胎牛血清的1640培養基; HpaA抗原初刺激濃度為0.2μmol/L時,抗原特異性CD4+T細胞的比例最高;在抗原刺激濃度0.2μmol/L條件下,細胞培養9 d時齣現特異性CD4+T細胞應答,且在第15天時達到高峰值;以不同肽段對特異性CD4+T細胞的IFN-γ應答水平檢測分析中顯示:針對本研究H.pylori感染箇體,HpaA抗原中可能存在一箇優勢應答的Th細胞錶位(HpaA220-237)。結論在人AB血清的1640培養基,0.2μmol/L為抗原刺激濃度,連續15 d擴增等培養條件下,在體外成功擴增齣H.pylori抗原特異性CD4+T淋巴細胞,可用于H.pylori抗原中Th錶位的篩選和鑒定,為錶位疫苗研究奠定實驗基礎。
목적:건립유문라간균( Helicobacter pylori,H.pylori)항원특이성CD4+T세포체외확증방법,병재Th표위사선중초보응용。방법종H.pylori감염양성환자중분리외주혈단개핵세포(PBMC),이중조점부소항원(HpaA)진행체외자격,분별모색불동혈청배양기、항원자격농도、배양시간등체외확증조건,병통과세포내인자염색화류식세포기술검측HpaA특이성CD4+T세포산생IFN-γ응답수평,종이건립H.pylori감염자항원특이성CD4+T림파세포적체외확증방법。동시,결합합성중첩태기술,대항원HpaA중가능적Th표위진행초보사사。결과재함인AB혈청적1640배양기중배양적항원특이성CD4+T세포적확증효솔우우함태우혈청적1640배양기; HpaA항원초자격농도위0.2μmol/L시,항원특이성CD4+T세포적비례최고;재항원자격농도0.2μmol/L조건하,세포배양9 d시출현특이성CD4+T세포응답,차재제15천시체도고봉치;이불동태단대특이성CD4+T세포적IFN-γ응답수평검측분석중현시:침대본연구H.pylori감염개체,HpaA항원중가능존재일개우세응답적Th세포표위(HpaA220-237)。결론재인AB혈청적1640배양기,0.2μmol/L위항원자격농도,련속15 d확증등배양조건하,재체외성공확증출H.pylori항원특이성CD4+T림파세포,가용우H.pylori항원중Th표위적사선화감정,위표위역묘연구전정실험기출。
Objective To screen an optimum method for in vitro culture of Helicobacter pylori-spe-cific CD4+T cells and apply it to immunodominant Th epitopes screening .Methods PBMCs were isolated from subjects positive for Helicobacter pylori infection and were stimulated with HpaA recombinant protein . Various induction conditions including serum containing mediums , concentrations of antigen and time were screened to obtain an optimum method for in vitro culture of Helicobacter pylori-specific CD4+T cells.The cells were harvested and stimulated using HpaA synthesized overlapping peptide pool .The percentage of an-tigen-specific CD4+T cells was evaluated by intercellular cytokine staining of interferon-γand the results were compared under different conditions .The possible immunodominant Th epitopes were screened by using synthetic overlapping peptides .Results Antigen-specific CD4+T cells were well cultured in RPMI 1640 culture medium containing human AB serum in comparison with those cultured in fetal bovine serum based medium.The highest percentage of antigen-specific CD4+T cells was achieved when stimulated with HpaA recombinant protein at the concentration of 0.2 μmol/L.CD4+T cells in response to the stimulation of 0.2μmol/L of HpaA recombinant protein was observed on the ninth day after culture and its peak was reached on the fifteenth day .A possible immunodominant Th epitope ( HpaA220-237 ) was screened in subjects with He-licobacter pylori-infection by using synthetic overlapping peptides .Conclusion Helicobacter pylori-specific CD4+T cells were successfully cultured in vitro by using RPMI 1640 culture medium containing human AB serum and stimulated with 0.2 μmol/L of HpaA recombinant protein for fifteen consecutive days .This cul-ture method could be applied to immunodominant Th epitopes screening and provide evidences for further in -vestigation on the development of Helicobacter pylori epitope-based vaccine .